Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
21 August 2017 |
Main ID: |
EUCTR2017-000958-19-ES |
Date of registration:
|
17/05/2017 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
First-line Esophageal Carcinoma Study with Chemo vs. Chemo + Pembrolizumab
|
Scientific title:
|
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590) - First-line Esophageal Carcinoma Study with Chemo vs. Chemo + Pembrolizumab |
Date of first enrolment:
|
07/07/2017 |
Target sample size:
|
700 |
Recruitment status: |
Authorised-recruitment may be ongoing or finished |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000958-19 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Argentina
|
Australia
|
Brazil
|
Canada
|
Chile
|
China
|
France
|
Germany
|
Guatemala
|
Hong Kong
|
Japan
|
Korea, Republic of
|
Malaysia
|
Russian Federation
|
Spain
|
Taiwan
|
Thailand
|
Turkey
|
United Kingdom
|
United States
| | | | |
Contacts
|
Name:
|
Investigación Clínica
|
Address:
|
Calle Josefa Valcárcel, 38
28027
Madrid
Spain |
Telephone:
|
+3491321 06 22 |
Email:
|
ensayos_clinicos@merck.com |
Affiliation:
|
Merck Sharp & Dohme de España S.A. |
|
Name:
|
Investigación Clínica
|
Address:
|
Calle Josefa Valcárcel, 38
28027
Madrid
Spain |
Telephone:
|
+3491321 06 22 |
Email:
|
ensayos_clinicos@merck.com |
Affiliation:
|
Merck Sharp & Dohme de España S.A. |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1.Be willing and able to provide written informed consent for the trial. The subject may also provide consent for Future Biomedical Research. However, the subject may participate in the trial without participating in Future Biomedical Research 2.Be = 18 years of age on the day of signing informed consent 3.Have histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the EGJ. a)Subjects with direct invasion into adjacent organs such as the aorta or trachea (T4b disease) should be closely evaluated for bleeding risk prior to enrollment and a Sponsor consultation before enrollment is required. b)Subjects with Siewert type 1 adenocarcinoma of the EGJ with known human epidermal growth factor receptor-2/neu (HER-2/neu)-positive tumors are not eligible. If HER-2/neu status is unknown, site should follow local standards for HER-2/neu testing 4.Have measurable disease per RECIST 1.1 as determined by the local site investigator/radiology assessment. A lesion(s) situated in a previously irradiated area can be considered a target lesion(s) if progression has been demonstrated and the lesion(s) is considered measurable per RECIST 1.1 criteria 5.Have an ECOG performance status of 0 to 1 6.Provide either a newly obtained or archival tissue sample for intratumoral immune-related GEP analysis and PD-L1 by immunohistochemistry analysis. Newly obtained tissue is preferred. Formalin-fixed, paraffin-embedded (FFPE) block specimens are preferred to slides. Repeat samples will be required if none of the samples submitted (archival or newly obtained) is adequate. For purposes of this study, newly obtained tissue refers to tissue that was collected between the last line of therapy and the first dose of study medication. a)Central laboratory confirmation of tumor tissue sample adequacy is required prior to subject randomization in the study. If multiple tumor samples are submitted, at least one of the samples must be confirmed to be adequate by the central laboratory prior to subject being enrolled. b)For subjects from whom newly obtained samples cannot be obtained (e.g., inaccessible or subject safety concern), an archival specimen may be submitted. c)If newly obtained tissue is provided and an archival tissue sample is available, it should also be provided to support evaluation of the clinical utility of immune-related GEP assessment and PD-L1 analysis by immunohistochemistry in newly obtained vs. archival tissue samples. However, a subject will not be excluded from participating in the study if he/she has provided newly obtained tissue and an archival tissue sample is not available or is otherwise insufficient for analysis 7. Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to randomization. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. If first dose is given > 72 hours post randomization, pregnancy test should be repeated within 72 hours of first dose 8.Female subjects of childbearing potential must be willing to use an adequate method of contraception as outlined in Section 5.7.2 – Contraception, for the course of the study through 120 days after the last dose of study therapy 9.Male subjects of childbearing potential must agree to use an adequate method of contraception as ou
Exclusion criteria: 1.Has locally advanced esophageal carcinoma that is resectable or potentially curable with radiation therapy (as determined by local investigator) 2.Has had previous therapy for advanced/metastatic adenocarcinoma or squamous cell cancer of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the EGJ. Subjects may have received prior neoadjuvant or adjuvant therapy as long as it was completed at least 6 months prior to randomization 3.Has had major surgery, open biopsy, or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of study treatment 4.Has a known additional malignancy that is progressing or requires active treatment. Exceptions include early-stage cancers (carcinoma in situ or Stage 1) treated with curative intent, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer, or in situ breast cancer that has undergone potentially curative therapy 5.Has known active central nervous system metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases confirmed by repeat imaging, and have not required steroids for at least 14 days before the first dose of trial treatment. This exception does not include carcinomatous meningitis, which is excluded regardless of clinical stability 6.Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed. Brief (i.e., < 7 days) use of systemic corticosteroids is allowed when use is considered standard of care by investigator 7.Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment 8.Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis 9.Has an active infection requiring systemic therapy 10.Has a history or current evidence of any condition (e.g., known deficiency of the enzyme dihydropyrimidine dehydrogenase), therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator 11.Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial 12.Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment 13.Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (i.e., CTLA-4, OX-40, CD137) or has previously participated in a pembrolizumab (MK-3475) cli
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
First-line treatment of subjects with locally advanced unresectable or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the esophagogastric junction MedDRA version: 20.0
Level: LLT
Classification code 10015366
Term: Esophageal carcinoma
System Organ Class: 100000004864
|
Therapeutic area: Diseases [C] - Cancer [C04]
|
Intervention(s)
|
Product Name: Pembrolizumab Product Code: MK-3475 Pharmaceutical Form: Solution for infusion INN or Proposed INN: PEMBROLIZUMAB CAS Number: 1374853-91-4 Current Sponsor code: MK-3475 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use
Trade Name: Cisplatin Accord 1 mg/mL Product Name: Cisplatin Pharmaceutical Form: Solution for infusion INN or Proposed INN: CISPLATIN CAS Number: 15663-27-1 Other descriptive name: CISPLATIN Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 1-
Trade Name: Fluorouracil Product Name: Fluorouracil Pharmaceutical Form: Solution for injection INN or Proposed INN: FLUOROURACIL CAS Number: 51-21-8 Other descriptive name: FLUOROURACIL Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 50-
|
Primary Outcome(s)
|
Secondary Objective: 1.Evaluate ORR per RECIST 1.1, as determined by blinded independent central review, between treatment arms in all subjects 2.Evaluate ORR per RECIST 1.1, as determined by blinded independent central review, between treatment arms in subjects whose tumors are GEP biomarker-positive 3.Evaluate PFS per irRECIST, as determined by blinded independent central review, between treatment arms in all subjects and in subjects whose tumors are GEP biomarker-positive 4.Evaluate duration of response (DOR) per RECIST 1.1, as determined by blinded independent central review, between treatment arms in all subjects and in subjects whose tumors are GEP biomarker-positive 5.Evaluate the safety and tolerability profile
Please refer to the protocol for the complete list
|
Main Objective: 1. To compare progression-free survival (PFS) per RECIST 1.1, as determined by blinded independent central review, between treatment arms in all subjects 2.To compare PFS per RECIST 1.1, as determined by blinded independent central review, between treatment arms in subjects whose tumors are GEP biomarker-positive 3.To compare overall survival (OS) between treatment arms in all subjects 4.To compare OS between treatment arms in subjects whose tumors are GEP biomarker-positive
|
Timepoint(s) of evaluation of this end point: Main Progression-free survival (PFS) and interim overall survival (OS) at IA (~31 months after trial starts) OS at final analysis (~40 months after trial starts)
|
Primary end point(s): 1.Progression-free survival (PFS) based o n RECIST 1.1 as assessed by blinded independent central review in all subjects 2. PFS based o n RECIST 1.1 as assessed by blinded independent central review in subjects whose tumors are GEP biomarker-positive 3. Overall survival (OS) in all subjects 4. OS in subjects whose tumors are GEP biomarker-positive
|
Secondary Outcome(s)
|
Secondary end point(s): 1.Objective response rate (ORR) based on RECIST 1.1 as assessed by blinded independent central review in all subjects 2. ORR based on RECIST 1.1 as assessed by blinded independent central review in subjects whose tumors are GEP biomarker-positive
|
Timepoint(s) of evaluation of this end point: Objective response rate (ORR), duration of response (DOR), Quality of Life, PD-L1 biomarker, and Safety at end of study
|
Secondary ID(s)
|
2017-000958-19-DE
|
MK-3475-590
|
Source(s) of Monetary Support
|
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|